164 related articles for article (PubMed ID: 22949224)
1. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Stockmann C; Sherwin CM; Zobell JT; Young DC; Waters CD; Spigarelli MG; Ampofo K
Pediatr Pulmonol; 2013 Mar; 48(3):211-20. PubMed ID: 22949224
[TBL] [Abstract][Full Text] [Related]
2. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
Zobell JT; Young DC; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Jun; 48(6):525-37. PubMed ID: 23359557
[TBL] [Abstract][Full Text] [Related]
3. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.
Young DC; Zobell JT; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Jan; 48(1):1-7. PubMed ID: 22949160
[TBL] [Abstract][Full Text] [Related]
4. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems.
Zobell JT; Young DC; Waters CD; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2012 Dec; 47(12):1147-58. PubMed ID: 22911974
[TBL] [Abstract][Full Text] [Related]
5. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
Zobell JT; Waters CD; Young DC; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Feb; 48(2):107-22. PubMed ID: 22949297
[TBL] [Abstract][Full Text] [Related]
6. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
Geller DE; Flume PA; Staab D; Fischer R; Loutit JS; Conrad DJ;
Am J Respir Crit Care Med; 2011 Jun; 183(11):1510-6. PubMed ID: 21471106
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin pharmacokinetics in adult cystic fibrosis.
Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
LeBel M
Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
[TBL] [Abstract][Full Text] [Related]
15. Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patients.
Cantón R; Máiz L; Escribano A; Olveira C; Oliver A; Asensio O; Gartner S; Roma E; Quintana-Gallego E; Salcedo A; Girón R; Barrio MI; Pastor MD; Prados C; Martínez-Martínez MT; Barberán J; Castón JJ; Martínez-Martínez L; Poveda JL; Vázquez C; de Gracia J; Solé A;
Arch Bronconeumol; 2015 Mar; 51(3):140-50. PubMed ID: 25614377
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
[TBL] [Abstract][Full Text] [Related]
17. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
[No Abstract] [Full Text] [Related]
20. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection.
Strandvik B; Hjelte L; Lindblad A; Ljungberg B; Malmborg AS; Nilsson-Ehle I
Scand J Infect Dis Suppl; 1989; 60():84-8. PubMed ID: 2756354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
